Adstiladrin
Adstiladrin ingredients
| Active ingredient | Strength |
|---|---|
| Nadofaragene Firadenovec | 300000000000 {VP}/mL |
What Adstiladrin is used for
The FDA lists the approved uses on the official label (below). In the EU, nadofaragene firadenovec is approved as Adstiladrin for:
Adstiladrin is indicated as monotherapy for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Adstiladrin
- Generic name
- Nadofaragene firadenovec-vncg
- Made by
- Ferring Pharmaceuticals Inc.
- Forms
- Suspension
- Given
- Intravesical
- FDA approval
- Biologic licence (BLA) BLA125700
- On the US market since
- 2023
Official information
- Adstiladrin prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Nadofaragene firadenovec-vncg)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Adstiladrin?
Adstiladrin (Nadofaragene firadenovec-vncg) is a cancer medicine made by Ferring Pharmaceuticals Inc., approved by the US FDA.
What are the ingredients of Adstiladrin?
Adstiladrin contains Nadofaragene Firadenovec (300000000000 {VP}/mL).
Is Adstiladrin approved in Europe?
The same active substance is approved in the EU as Adstiladrin.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA